30 June 2020 

Gilead Sciences has set the price of its investigational Covid-19 drug remdesivir at $390 per vial for the US and governments of other developed countries. Current treatment patterns reveal that most patients may require a five-day treatment course, which involves six vials of remdesivir, pricing the course at $2,340 per patient.

Bharat Biotech has secured regulatory approval from the Drug Controller General of India (DCGI) to advance its Covid-19 vaccine candidate, Covaxin, into human clinical trials. This marks the first regulatory approval for India’s domestic vaccine to enter trials. DCGI’s approval will enable the company to conduct Phase I and II studies, which are set to begin next month.

Data from the UK’s RECOVERY clinical trial being has demonstrated no benefit with lopinavir-ritonavir, a commonly used HIV medication marketed by AbbVie, in treating patients hospitalised with Covid-19. The researchers also noted no evidence of beneficial impact on the risk of progression to mechanical ventilation or duration of hospital stay.

Mexico is in discussions with the Chinese government and private Chinese laboratories, along with the University of Oxford and AstraZeneca about conducting human trials for Covid-19 vaccine candidates, reported Reuters. Mexican deputy foreign minister Martha Delgado said that the country is currently exploring its capabilities to buy, manufacture and distribute vaccines.